Target intelligence / Profile preview

Novel transcript, antisense to NRCAM

Molecular classification: Long non-coding RNA (lncRNA), Antisense RNA

Overview

ENSG00000303545, described as "novel transcript, antisense to NRCAM," is annotated as a long non-coding RNA (lncRNA) whose sequence is complementary to and overlaps with the NRCAM gene transcript. No published data support its protein-coding potential, known disease associations, or role as a drug target. There is currently no information about biological function, druggability, or therapeutic relevance for this transcript. Its assignment as a gene or target is based primarily on computational prediction without experimental validation[2][3]. It should not be treated as a canonical therapeutic target.

Other names: novel transcript, antisense to NRCAMENSG00000303545

Beyond the preview

Go deeper on Novel transcript, antisense to NRCAM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to NRCAM.

Explore the full profile